Sign Up Today and Learn More About MacuLogix Stock
Invest in or calculate the value of your shares in MacuLogix or other pre-IPO companies through EquityZen's platform.
MacuLogix Stock
Detecting and tracking age-related macular degeneration
About MacuLogix Stock
Founded
2004
Headquarters
Hummelstown, PA, US
Total Funding
63.8M
Industries
Health Care
MacuLogix aims to detect early and track age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD.
MacuLogix Press Mentions
Stay in the know about the latest news on MacuLogix
LumiThera, Inc. Announces Purchase of MacuLogix Assets
prnewswire • Jul 26, 2022
MacuLogix Introduces the AdaptDx Pro, Guided by Theia
newswire • Jan 18, 2020
MacuLogix Hires Christine W. Silverberg as Director of National Accounts
newswire • Nov 15, 2019
'Practical Strategies for Preventing Blindness Caused by AMD' Offers Clear Framework on How to Manage AMD in Optometric Practice
newswire • Oct 23, 2019
MacuLogix Raises $3.6M in Series A Funding
finsmes • Sep 29, 2015
MacuLogix Management
Leadership team at MacuLogix
Co-founder and Chief Scientific Officer
Gregory R. Jackson
CEO
Bill McPhee
Join now and verify your accreditation status to gain access to:
- MacuLogix Current Valuation
- MacuLogix Stock Price
- MacuLogix Management
- Available deals in MacuLogix and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- MacuLogix Cap Table and Funding History by Share Class and Liquidity Preferences
- MacuLogix Revenue and Financials
- MacuLogix Highlights
- MacuLogix Business Model
- MacuLogix Risk Factors
- MacuLogix Research Report from SACRA Research
Trading MacuLogix Stock
How to invest in MacuLogix stock?
Accredited investors can buy pre-IPO stock in companies like MacuLogix through EquityZen funds. These investments are made available by existing MacuLogix shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell MacuLogix stock?
Shareholders can sell their MacuLogix stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."